Company / R&D Expense
Tonix Pharmaceuticals Holding Corp. R&D Expense History
FY2023-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$40.0M
FY2025
5-year range
$40.0M / $86.7M
FY2023-FY2025
Trend
-53.9%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Declined from $82M to $40M over the past 2 years.
Based on SEC 10-K filings.
$40M in FY2025.
Declined from $82M to $40M over the past 2 years.
R&D Expense over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, r&d expense decreased 53.9% year-over-year.
Company context
Key Data Points
- Altman Z-Score -0.56 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $40.0M | -53.9% |
| FY2024 | $86.7M | +5.8% |
| FY2023 | $81.9M | - |
As of FY2025 · SEC Form 10-K · Last checked Jun 28, 2026